Ultrasensitive liquid biopsy tech spots cancer earlier than standard methods

Cancer cell during cell division. Credit: National Institutes of Health An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center (NYGC) and Memorial Sloan Kettering Cancer Center (MSK). The new technology has the potential to improve cancer care with the very early detection of recurrence and close monitoring of tumor response during therapy. In the study, which appears June 14 in Nature Medicine, the researchers showed Read More

Related posts:

  1. New technology can detect kidney diseases earlier than standard methods
  2. Development of new techniques and clinical applications of liquid biopsy in lung cancer management
  3. Novel liquid biopsy methodology enables monitoring of disease evolution in patients with metastatic prostate cancer
  4. Clinical trial could lead to new ‘gold standard’ test for prostate cancer detection
  5. New combination therapy shows promise for bladder cancer patients unresponsive to standard treatment
  6. Dallas cancer tech company develops new blood test it says can catch tumors early
  7. HMN: Red spots on skin, not itchy? Possible causes & treatment options in 2025
  8. Liquid low-calorie or low-carb keto diet can reverse type 2 diabetes, research shows

Leave a Reply

Your email address will not be published. Required fields are marked *